Imaging Intratumor Heterogeneity: Role in Therapy Response, Resistance, and Clinical Outcome

Tumors exhibit genomic and phenotypic heterogeneity, which has prognostic significance and may influence response to therapy. Imaging can quantify the spatial variation in architecture and function of individual tumors through quantifying basic biophysical parameters such as CT density or MRI signal relaxation rate; through measurements of blood flow, hypoxia, metabolism, cell death, and other phenotypic features; and through mapping the spatial distribution of biochemical pathways and cell signaling networks using PET, MRI, and other emerging molecular imaging techniques. These methods can establish whether one tumor is more or less heterogeneous than another and can identify subregions with differing biology. In this article, we review the image analysis methods currently used to quantify spatial heterogeneity within tumors. We discuss how analysis of intratumor heterogeneity can provide benefit over more simple biomarkers such as tumor size and average function. We consider how imaging methods can be integrated with genomic and pathology data, instead of being developed in isolation. Finally, we identify the challenges that must be overcome before measurements of intratumoral heterogeneity can be used routinely to guide patient care. Clin Cancer Res; 21(2); 249–57. ©2014 AACR.

[1]  Arvind P. Pathak,et al.  Multiscale and multi-modality visualization of angiogenesis in a human breast cancer model , 2014, Angiogenesis.

[2]  J R Griffiths,et al.  Tumour dose response to the antivascular agent ZD6126 assessed by magnetic resonance imaging , 2003, British Journal of Cancer.

[3]  Geoff J M Parker,et al.  Quantifying Antivascular Effects of Monoclonal Antibodies to Vascular Endothelial Growth Factor: Insights from Imaging , 2009, Clinical Cancer Research.

[4]  D. Collins,et al.  Advanced solid tumors treated with cediranib: comparison of dynamic contrast-enhanced MR imaging and CT as markers of vascular activity. , 2012, Radiology.

[5]  Harry J de Koning,et al.  Limited value of shape, margin and CT density in the discrimination between benign and malignant screen detected solid pulmonary nodules of the NELSON trial. , 2008, European journal of radiology.

[6]  E. Rofstad,et al.  Intratumor heterogeneity in blood perfusion in orthotopic human melanoma xenografts assessed by dynamic contrast‐enhanced magnetic resonance imaging , 2005, Journal of magnetic resonance imaging : JMRI.

[7]  N. van Bruggen,et al.  Quantification of viable tumor microvascular characteristics by multispectral analysis , 2008, Magnetic resonance in medicine.

[8]  R. Coleman,et al.  Recommendations on the Use of 18F-FDG PET in Oncology , 2008, Journal of Nuclear Medicine.

[9]  R. Solé,et al.  Metapopulation dynamics and spatial heterogeneity in cancer , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[10]  W. Niessen,et al.  Quantification of Heterogeneity as a Biomarker in Tumor Imaging: A Systematic Review , 2014, PloS one.

[11]  E. Rofstad,et al.  Temporal heterogeneity in blood supply in human tumor xenografts. , 2008, Neoplasia.

[12]  Susan M. Astley,et al.  Classification of breast tissue by texture analysis , 1992, Image Vis. Comput..

[13]  Functional principal component analyses of biomedical images as outcome measures , 2010 .

[14]  M. Junttila,et al.  Influence of tumour micro-environment heterogeneity on therapeutic response , 2013, Nature.

[15]  T. Powles,et al.  Sequential FDG-PET/CT as a Biomarker of Response to Sunitinib in Metastatic Clear Cell Renal Cancer , 2011, Clinical Cancer Research.

[16]  Robert M. Haralick,et al.  Textural Features for Image Classification , 1973, IEEE Trans. Syst. Man Cybern..

[17]  A. D. Van den Abbeele,et al.  CT and PET: early prognostic indicators of response to imatinib mesylate in patients with gastrointestinal stromal tumor. , 2007, AJR. American journal of roentgenology.

[18]  M. Hatt,et al.  Reproducibility of Tumor Uptake Heterogeneity Characterization Through Textural Feature Analysis in 18F-FDG PET , 2012, The Journal of Nuclear Medicine.

[19]  Xiangyu Yang,et al.  Quantifying Tumor Vascular Heterogeneity with Dynamic Contrast-Enhanced Magnetic Resonance Imaging: A Review , 2011, Journal of biomedicine & biotechnology.

[20]  S. Orel,et al.  BI-RADS categorization as a predictor of malignancy. , 1999, Radiology.

[21]  V. Goh,et al.  Assessment of primary colorectal cancer heterogeneity by using whole-tumor texture analysis: contrast-enhanced CT texture as a biomarker of 5-year survival. , 2013, Radiology.

[22]  D L Buckley,et al.  Enhancing fraction measured using dynamic contrast-enhanced MRI predicts disease-free survival in patients with carcinoma of the cervix , 2009, British Journal of Cancer.

[23]  Samuel H. Hawkins,et al.  Reproducibility and Prognosis of Quantitative Features Extracted from CT Images. , 2014, Translational oncology.

[24]  D. Appelbaum,et al.  Interobserver variability among measurements of the maximum and mean standardized uptake values on 18F-FDG PET/CT and measurements of tumor size on diagnostic CT in patients with pulmonary tumors , 2010, Acta radiologica.

[25]  Timothy D Johnson,et al.  Prospective Analysis of Parametric Response Map–Derived MRI Biomarkers: Identification of Early and Distinct Glioma Response Patterns Not Predicted by Standard Radiographic Assessment , 2011, Clinical Cancer Research.

[26]  A. Ozonoff,et al.  FDG PET/CT interobserver agreement in head and neck cancer: FDG and CT measurements of the primary tumor site , 2012, Nuclear medicine communications.

[27]  D. Buckley,et al.  Heterogeneity analysis of Gd-DTPA uptake: improvement in breast lesion differentiation. , 1999, Journal of computer assisted tomography.

[28]  H. Peitgen,et al.  Chaos and Fractals , 2004 .

[29]  A. Bjørnerud,et al.  Glioma grading by using histogram analysis of blood volume heterogeneity from MR-derived cerebral blood volume maps. , 2008, Radiology.

[30]  Susan M. Chang,et al.  Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[31]  J. Brenton,et al.  Evaluation of nonenhancing tumor fraction assessed by dynamic contrast-enhanced MRI subtraction as a predictor of decrease in tumor volume in response to chemoradiotherapy in advanced cervical cancer. , 2010, AJR. American journal of roentgenology.

[32]  R. Gillies,et al.  Quantitative imaging in cancer evolution and ecology. , 2013, Radiology.

[33]  I. Ellis,et al.  The positive predictive value of mammographic signs: a review of 425 non-palpable breast lesions. , 1996, Clinical radiology.

[34]  Chieko Azuma,et al.  Multispectral quantification of tissue types in a RIF‐1 tumor model with histological validation. Part I , 2007, Magnetic resonance in medicine.

[35]  G. Heppner Tumor heterogeneity. , 1984, Cancer research.

[36]  R. Beroukhim,et al.  Molecular definition of breast tumor heterogeneity. , 2007, Cancer cell.

[37]  R. Buchert,et al.  Gene Expression Patterns and Tumor Uptake of 18F-FDG, 18F-FLT, and 18F-FEC in PET/MRI of an Orthotopic Mouse Xenotransplantation Model of Pancreatic Cancer , 2008, Journal of Nuclear Medicine.

[38]  Paul S Mischel,et al.  Quantitative volumetric analysis of conventional MRI response in recurrent glioblastoma treated with bevacizumab. , 2011, Neuro-oncology.

[39]  V. Goh,et al.  Assessment of response to tyrosine kinase inhibitors in metastatic renal cell cancer: CT texture as a predictive biomarker. , 2011, Radiology.

[40]  Michael V Knopp,et al.  Microarray gene expression analysis of murine tumor heterogeneity defined by dynamic contrast-enhanced MRI. , 2002, Molecular imaging.

[41]  Quantitative analysis of whole‐tumor Gd enhancement histograms predicts malignant transformation in low‐grade gliomas , 2007, Journal of magnetic resonance imaging : JMRI.

[42]  Chong-Yung Chi,et al.  Tissue-Specific Compartmental Analysis for Dynamic Contrast-Enhanced MR Imaging of Complex Tumors , 2011, IEEE Transactions on Medical Imaging.

[43]  P. Noker,et al.  Variability of tumor response to chemotherapy II. Contribution of tumor heterogeneity , 2004, Cancer Chemotherapy and Pharmacology.

[44]  A. Padhani,et al.  Multiparametric imaging of tumor response to therapy. , 2010, Radiology.

[45]  R. L. Butterfield,et al.  Multispectral analysis of magnetic resonance images. , 1985, Radiology.

[46]  M. Giger,et al.  Volumetric texture analysis of breast lesions on contrast‐enhanced magnetic resonance images , 2007, Magnetic resonance in medicine.

[47]  J. Waterton,et al.  Use of dynamic contrast-enhanced MRI to evaluate acute treatment with ZD6474, a VEGF signalling inhibitor, in PC-3 prostate tumours , 2003, British Journal of Cancer.

[48]  Carol Walker,et al.  Apparent diffusion coefficients in oligodendroglial tumors characterized by genotype , 2007, Journal of magnetic resonance imaging : JMRI.

[49]  H. Fine,et al.  A phase II trial of single-agent bevacizumab in patients with recurrent anaplastic glioma. , 2011, Neuro-oncology.

[50]  Geoff J M Parker,et al.  Indexed distribution analysis for improved significance testing of spatially heterogeneous parameter maps: Application to dynamic contrast‐enhanced MRI biomarkers , 2013, Magnetic resonance in medicine.

[51]  Corbin E. Meacham,et al.  Tumour heterogeneity and cancer cell plasticity , 2013, Nature.

[52]  J. Marcus,et al.  First-line erlotinib and bevacizumab in patients with locally advanced and/or metastatic non-small-cell lung cancer: a phase II study including molecular imaging. , 2011, Annals of oncology : official journal of the European Society for Medical Oncology.

[53]  Arnau Oliver,et al.  A review of automatic mass detection and segmentation in mammographic images , 2010, Medical Image Anal..

[54]  R. Arceci Intratumor Heterogeneity and Branched Evolution Revealed by Multiregion Sequencing , 2012 .

[55]  P. A. Futreal,et al.  Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. , 2012, The New England journal of medicine.

[56]  G Johnson,et al.  Histogram analysis versus region of interest analysis of dynamic susceptibility contrast perfusion MR imaging data in the grading of cerebral gliomas. , 2007, AJNR. American journal of neuroradiology.

[57]  A. Jackson,et al.  Dynamic contrast-enhanced MRI in clinical trials of antivascular therapies , 2012, Nature Reviews Clinical Oncology.

[58]  C. Swanton Intratumor heterogeneity: evolution through space and time. , 2012, Cancer research.

[59]  B. Frieden,et al.  Adaptive therapy. , 2009, Cancer research.

[60]  D. D. Maki,et al.  Radiogenomic analysis of breast cancer using MRI: a preliminary study to define the landscape. , 2012, AJR. American journal of roentgenology.

[61]  Li Lan,et al.  Fractal analysis of mammographic parenchymal patterns in breast cancer risk assessment. , 2007, Academic radiology.

[62]  P. Lambin,et al.  Decoding tumour phenotype by noninvasive imaging using a quantitative radiomics approach , 2014, Nature Communications.

[63]  Matthew S. Brown,et al.  Recurrent glioblastoma multiforme: ADC histogram analysis predicts response to bevacizumab treatment. , 2009, Radiology.

[64]  R. Jain,et al.  Spatial heterogeneity in tumor perfusion measured with functional computed tomography at 0.05 microliter resolution. , 1994, Cancer research.

[65]  F E Turkheimer,et al.  Quantification of intra-tumour cell proliferation heterogeneity using imaging descriptors of 18F fluorothymidine-positron emission tomography , 2013, Physics in medicine and biology.

[66]  N. van Bruggen,et al.  Quantification of tumor tissue populations by multispectral analysis , 2004, Magnetic resonance in medicine.

[67]  Vladimir Ponomarev,et al.  Molecular Imaging of Temporal Dynamics and Spatial Heterogeneity of Hypoxia-Inducible Factor-1 Signal Transduction Activity in Tumors in Living Mice , 2004, Cancer Research.

[68]  Albert Lai,et al.  Apparent diffusion coefficient histogram analysis stratifies progression-free and overall survival in patients with recurrent GBM treated with bevacizumab: a multi-center study , 2012, Journal of Neuro-Oncology.

[69]  John C Waterton,et al.  Qualification of imaging biomarkers for oncology drug development. , 2012, European journal of cancer.

[70]  R. Jain,et al.  2H-nuclear magnetic resonance imaging of tumor blood flow: spatial and temporal heterogeneity in a tissue-isolated mammary adenocarcinoma. , 1992, Cancer research.

[71]  N. Just,et al.  Improving tumour heterogeneity MRI assessment with histograms , 2014, British Journal of Cancer.

[72]  Siqing Shan,et al.  The pervasive presence of fluctuating oxygenation in tumors. , 2008, Cancer research.

[73]  W J Niessen,et al.  Heterogeneity in DCE-MRI parametric maps: a biomarker for treatment response? , 2011, Physics in medicine and biology.

[74]  R. Cox,et al.  Acute Effects of Bevacizumab on Glioblastoma Vascularity Assessed with DCE-MRI and Relation to Patient Survival , 2009 .

[75]  P. Grigsby,et al.  Intratumoral Metabolic Heterogeneity of Cervical Cancer , 2008, Clinical Cancer Research.

[76]  C. Sotak,et al.  Multispectral tissue characterization in a RIF‐1 tumor model: Monitoring the ADC and T2 responses to single‐dose radiotherapy. Part II , 2007, Magnetic resonance in medicine.

[77]  Stefan Delorme,et al.  Pharmacokinetic analysis of malignant pleural mesothelioma-initial results of tumor microcirculation and its correlation to microvessel density (CD-34). , 2008, Academic radiology.

[78]  G Johnson,et al.  Glial neoplasms: dynamic contrast-enhanced T2*-weighted MR imaging. , 1999, Radiology.

[79]  A. Jackson,et al.  Quantitative imaging biomarkers in the clinical development of targeted therapeutics: current and future perspectives. , 2008, The Lancet. Oncology.

[80]  M. Dewhirst,et al.  Spatial heterogeneity and oxygen dependence of glucose consumption in R3230Ac and fibrosarcomas of the Fischer 344 rat. , 2005, Cancer research.

[81]  H. Shim,et al.  Molecular portraits of intratumoral heterogeneity in human ovarian cancer. , 2011, Cancer letters.

[82]  Bal Sanghera,et al.  Reproducibility of 2D and 3D fractal analysis techniques for the assessment of spatial heterogeneity of regional blood flow in rectal cancer. , 2012, Radiology.

[83]  Rakesh K. Jain,et al.  Spatial Heterogeneity in Tumor Perfusion Measured with Functional Computed Tomography at 0.05 µl Resolution , 1994 .

[84]  Scott Fields,et al.  Mapping pathophysiological features of breast tumors by MRI at high spatial resolution , 1997, Nature Medicine.

[85]  John O. Prior,et al.  Early prediction of response to sunitinib after imatinib failure by 18F-fluorodeoxyglucose positron emission tomography in patients with gastrointestinal stromal tumor. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[86]  Isabelle Salmon,et al.  Comparison of 18F-FDG and 11C-methionine for PET-guided stereotactic brain biopsy of gliomas. , 2004, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[87]  Brandon Whitcher,et al.  DCE-MRI biomarkers of tumour heterogeneity predict CRC liver metastasis shrinkage following bevacizumab and FOLFOX-6 , 2011, British Journal of Cancer.

[88]  Geoff J M Parker,et al.  Imaging Tumor Vascular Heterogeneity and Angiogenesis using Dynamic Contrast-Enhanced Magnetic Resonance Imaging , 2007, Clinical Cancer Research.

[89]  Brandon Whitcher,et al.  Quantifying spatial heterogeneity in dynamic contrast‐enhanced MRI parameter maps , 2009, Magnetic resonance in medicine.